Requirement for Phosphatidylinositol 3'-kinase to Protect Hemopoietic Progenitors Against Apoptosis Depends Upon the Extracellular Survival Factor
Overview
Authors
Affiliations
Hemopoietic growth factors promote survival of progenitor cells by preventing their apoptotic death. Recently, phosphatidylinositol 3'-kinase (PI 3-kinase) has been shown to be integral in the pathway by which insulin and nerve growth factor prevent apoptosis. In this work, we show that IL-3-dependent FDCP-1/Mac-1 murine hemopoietic progenitors express receptors for another growth factor, insulin-like growth factor-I (IGF-I), and that both IL-3 and IGF-I stimulate PI 3-kinase activity. We then demonstrate that IGF-I shares with IL-3 the properties of significantly promoting proliferation and enhancing survival of myeloid progenitor cells at concentrations as low as 3 ng/ml. IL-3 and IGF-I efficiently promote cell survival in the presence of inhibitors of either RNA synthesis (actinomycin D) or mitosis (mitomycin C), suggesting that both ligands promote survival by a process that is largely independent of RNA synthesis. To determine whether PI 3-kinase mediates IL-3- and IGF-I-induced inhibition of apoptosis, FDCP-1/Mac-1 cells were incubated with the PI 3-kinase inhibitor, wortmannin. While wortmannin inhibited both basal and IGF-I- and IL-3-induced PI 3-kinase enzyme activity, it did not affect the ability of IL-3 to protect FDCP-1/Mac-1 cells from apoptosis, even though it abrogated the IGF-I-induced inhibition of apoptosis. These data demonstrate that even though activation of PI 3-kinase is a pleiotropic feature of both IL-3 and IGF-I receptors in myeloid progenitors, prevention of apoptosis by IL-3 but not IGF-I is independent of PI 3-kinase. Survival of hemopoietic progenitors is therefore maintained by at least two different intracellular signaling pathways, one requiring PI 3-kinase and one that does not.
Amarante-Mendes G, Rana A, Datoguia T, Hamerschlak N, Brumatti G Pharmaceutics. 2022; 14(1).
PMID: 35057108 PMC: 8780254. DOI: 10.3390/pharmaceutics14010215.
CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.
Brunner-Weinzierl M, Rudd C Front Immunol. 2018; 9:2737.
PMID: 30542345 PMC: 6277866. DOI: 10.3389/fimmu.2018.02737.
Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation.
Zhou D, Deoliveira D, Kang Y, Choi S, Li Z, Chao N Int J Radiat Oncol Biol Phys. 2012; 85(4):1141-8.
PMID: 23021438 PMC: 3562560. DOI: 10.1016/j.ijrobp.2012.08.014.
Miura Y, Murata Y, Utsumi K, Takahata K, Tada M, Otsuki T Environ Health Prev Med. 2011; 10(4):184-9.
PMID: 21432138 PMC: 2723312. DOI: 10.1007/BF02897709.
Chen B, Deoliveira D, Spasojevic I, Sempowski G, Jiang C, Owzar K PLoS One. 2010; 5(6):e11056.
PMID: 20585403 PMC: 2886847. DOI: 10.1371/journal.pone.0011056.